MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
MoonLake Immunotherapeutics reported Week 52 Phase 3 VELA results for sonelokimab (SLK) in moderate-to-severe hidradenitis suppurativa. According to the company, 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100; 26.0% reached IHS4-100. No new safety signals were seen. Interim VELA-TEEN Week 24 data showed ~68% HiSCR75. The company plans a BLA submission by end-September 2026 and will host an Investor Day webcast June 22, 2026.
How this was made
The 30-second read
Why it matters
The disclosed Week 52 efficacy durability (HiSCR75 ~67%, HiSCR100 ~33%, IHS4-100 ~26%) and patient-reported outcome improvements, alongside “no new safety signals,” strengthen the case for regulatory submission and potential label differentiation; the Investor Day is a near-term catalyst for narrative and guidance on upcoming steps.
Market read
This is a late-stage clinical readout plus a concrete regulatory timeline (BLA expected end-Sep 2026) and a scheduled Investor Day, which can move biotech sentiment and positioning.
What to watch
The text provides limited detail on statistical significance, subgroup durability, and how FDA will interpret endpoints/label strategy—key drivers for valuation beyond headline response rates.
Background
MoonLake is a clinical-stage biotech developing sonelokimab (SLK) for hidradenitis suppurativa (HS) and is running Phase 3 VELA-1/VELA-2 plus VELA-TEEN.
Ticker impact
MoonLake reports Week 52 Phase 3 VELA results for sonelokimab (SLK) in hidradenitis suppurativa and confirms an Investor Day on June 22, 2026.
Near-term upside bias into the June 22 Investor Day, with follow-through contingent on investor focus on BLA timing and FDA label strategy.
The article discloses detailed Week 52 response rates (HiSCR75/HiSCR100/IHS4-100), patient-reported outcome improvements, and explicitly states no new safety signals, plus a concrete next milestone (BLA expected end-Sep 2026).
Market effects
Biotech/immune-inflammatory pipeline sentiment may improve for HS-focused development and investor appetite for late-stage dermatology immunotherapies.
Limited direct regional impact; primarily US-listed biotech sentiment.
Global HS treatment landscape read-through may affect peer valuation expectations, though the article provides no new peer-specific regulatory or trial events.
Counterpoint
Despite strong Week 52 numbers, the article is still pre-BLA; investors may discount efficacy comparisons to competitors and wait for FDA feedback and label specifics.
Key entities
- companyMoonLake Immunotherapeutics
NASDAQ-listed clinical-stage biotech announcing Week 52 Phase 3 VELA results for SLK and scheduling an Investor Day.
- drugSonelokimab (SLK)
MoonLake’s investigational nanobody for HS; reported Week 52 efficacy and safety in VELA and interim Week 24 data in VELA-TEEN.
- regulatorFDA
Regulatory body for the planned BLA submission and label strategy guidance referenced by the company.
